October 17, 2016 – Executive search firm Slone Partners has placed Matthew Watson as the new chief executive officer of Westox Labs. In his new role, Mr. Watson will lead and oversee all aspects of the business, including sales, marketing, operations, finance, billing, and compliance.
With over 25 years of experience, Mr. Watson is a veteran healthcare executive and entrepreneur who has led and counseled several organizations. Prior to joining Westox Labs, he served as a clinical laboratory consultant, where he provided professional consulting services on strategic planning, laboratory design & implementation, billing & reimbursement strategy, and operations management.
Before this, he founded and served as CEO of PathCentral, a national provider of integrated pathology business solutions. He also served as CEO of Pathology Business Services, founded and served as CEO of Combimatrix Molecular Diagnostics, and worked as COO at US LABS (now LabCorp/Integrated Oncology).
“I am extremely excited by this opportunity and honored to follow in the footsteps of current CEO, Mike Gilles, who, together with his senior leadership team, has created a toxicology laboratory of the highest quality,” said Mr. Watson. “I plan on building on Mike’s success by significantly expanding Westox’s market reach while maintaining the quality, turnaround time, and customer service the company has become known for.”
He said he was grateful to Slone Partners for connecting him with an organization that is “a perfect fit for my background, experience and management style.”
No Stranger to Finding Genetics Leaders
Westox Labs is a fast-growing Southern California toxicology company offering a full line of superior laboratory-based and onsite drug testing solutions. Dedicated to providing first class service and support, the organization uses the advanced laboratory technology paired with quality control mechanisms to ensure a high level of accuracy and consistency.
Slone Partners is no stranger to finding leaders for the expanding genetics sector. Over the past several months, the firm has recruited Peter Maimonis Ph.D., as senior vice president and chief science officer of Metamark Genetics; a chief clinical laboratory officer for personalized medicine company Celmatix; a chief medical officer at commercial stage, molecular genetics diagnostic company Signal Genetics; a VP of managed care at medicine company Genomind; and the president of North America at cancer detection company Abcodia.
The firm is a nationally recognized senior level recruitment provider that specializes in delivering executive, management and leadership talent for the diagnostic, biopharmaceutical, healthcare information technology and laboratory testing industries. It has offices in Boston, New York, Washington, D.C. and San Francisco.
This summer, Slone Partners named Leslie Loveless as its new chief executive officer. She succeeds Adam Slone, who founded the firm in 2000. Ms. Loveless joined Slone Partners in 2007 and was promoted to chief operating officer in 2014. Prior to joining the firm, she served as director of training and development for AmeriPath.
Contributed by Dale M. Zupsansky, Managing Editor, Hunt Scanlon Media